Alzheimer's Risk Elevated as Well

Diabetics from page 1

istry, who were surveyed from 1994 to 1996. The mean age at baseline was 66 years; 66% were white, 10% black, and the rest were Hispanic, Asian, or Native American.

The patients were followed until 2005. By then, 11% had developed new-onset dementias. Hemoglobin A_{1c} (Hb A_{1c}) was significantly associated with the incidence of dementia. Patients with the highest HbA_{1c} (15% and higher) were the most likely to develop dementia, with an elevated risk of 78% compared with those whose levels

were below 10%. Diabetic patients are advised to keep their HbA_{1c} below 7%.

Those with HbA1c levels of 12%-15% were 22% more likely to develop dementia. while those whose levels were between 10% and 11.9% had a 16% increased risk. The increased risks remained significant even after adjusting for age, race, gender, weight, and diabetes treatment.

This shows us that tight glycemic control continues to be as important as patients' age," Dr. Whitmer said at the meeting, presented by the Alzheimer's Association. "And it will become more and more important as we experience the epidemic of obesity in the United States."

Even patients with borderline diabetes should be aware of controlling their glucose levels, said Dr. Laura Fratiglioni, who presented research completed by her colleague, Dr. Weili Xu of the Karolinska Institute, Stockholm.

Their 9-year study tracked the incidence of dementia in 1,173 subjects older than 75 years who were free of both dementia and diabetes at baseline.

The subjects were examined three times during the study period; each exam in-

BRIEF SUMMARY CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

TRICOR[®] 48 mg and 145 mg (fenofibrate tablets)

\mathbf{R} only

CONTRAINDICATIONS dicated in patients who exhibit hypersensitivity to TRICOR is

fenofibrate. TRICOR is contraindicated in patients with hepatic or severe renal dysfunction, including primary biliary cirthosis, and patients with unexplained persistent liver function abnormality. TRICOR is contraindicated in patients with preexisting gallbladder disease (see WARNINGS).

TRICOR is contraindicated in patients with preexisting gallbladder disease (see WARNINGS).
WARNINGS
Liver Function: Fenofibrate at doses equivalent to 96 mg to 145 mg TRICOR per day has been associated with increases in serum transaminases [AST (SGOT) or ALT (SGPT)]. In a pooled analysis of 10 placebo-controlled trials, increases to > 3 times the upper limit of normal occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo.
When transaminase determinations were followed either after discontinuation of treatment or during continued treatment, a return to normal limits was usually observed. The incidence of increases in transaminases related to fenofibrate therapy appear to be dose related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper limit of normal was 13% in patients receiving dosages equivalent to 96 mg to 145 mg TRICOR per day and was 0% in those receiving dosages equivalent to 48 mg or less TRICOR per day, or placebo. Hepatocellular, chronic active and cholestatic hepatitis associatio with fenofibrate therapy have been reported after exposures of weeks to several years. In extremely rare cases, cirhonis has been reported in association with thronic active hepatitis.
Regular periodic monitoring of liver function, including serum ALT (SGPT) should be performed for the duration of therapy with TRICOR, and therapy discontinued if enzyme levels persist above three times the normal limit.
Cholelithiasis: Fenofibrate, like clofibrate and gemfibrozil, may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected, gulbladder studies are indicated. TRICOR therapy should be discontinued if gallstones are found.
Concomitant Oral Anticoagulants: Caution should be exercised when anticoagulants are given in conjunction with TRICOR because of the prothrombin time/TNR the designed level to pre

Increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3' -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively. The combined use of fibric acid derivatives and HMG-CoA reductase inhibitors has been associated, in the absence of a marked pharmacokinetic interaction, in numerous case reports, with rhabdomyolysis, markedly elevated creatine kinase (CK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure. The use of fibrates alone, including TRICOR, may occasionally be associated with myositis, myopathy, or thabdomyolysis. Patients receiving TRICOR and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myopathy, including serum creatine kinase level determination. If myopathy/including serum creatine Kinase level determination. If myopathy/including serum creatine **Mortality:** The effect of TRICOR on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established.

Mortality: The effect of TRICOR on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established. Other Considerations: In the Coronary Drug Project, a large study of post myocardial infarction of patients treated for 5 years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was however, a difference in the rate of cholelithiasis and cholecystitis requiring surgery between the two groups (3.0% vs. 1.8%). Because of chemical, pharmacological, and clinical similarities between TRICOR (fenofibrate tablets), Atromid-S (clofibrate), and Lopid (gemfibrozil), the adverse findings in 4 large randomized, placebo-controlled clinical studies with these other fibrate drugs may also apply to TRICOR. In a study conducted by the World Health Organization (WHO), 5000 subjects without known coronary artery disease were treated with placebo or

clinical studies with these other thrate drugs may also apply to TRICOR. In a study conducted by the World Health Organization (WHO), 5000 subjects without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional one year. There was a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p=<0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. This appeared to confirm the higher risk of gallbladder disease seen in clofibrate-treated patients studied in the Coronary Drug Project. The Helsinki Heart Study was a large (n=4081) study of middle-aged men without a history of coronary artery disease. Subjects received either placebo or genfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the genfibrozil randomization group but did not achieve statistical significance (p=0.19, 95% confidence interval for relative risk G?P=91-1.64). Although cancer deaths trended higher in the genfibrozil group (p=0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of death from any cause was not shown to be different than that seen in the 9 year follow-up data from World Health Organization study (RR=1.29). Similarly, the numerical excess of gallbladder surgeries in the genfibrozil group did not differ statistically from that observed in the WHO study.

observed in the WHO study. A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac deaths trended higher in the gemfibrozil the study of the stud practice for 5 years. Antiologic tartials deals it ended ingret in the germitory group, this was not statistically significant (hazard ratio 2.2, 95% confidence interval: 0.94-5.05). The rate of gallbladder surgery was not statistically significant between study groups, but did trend higher in the germfibrozil group, (1.9% vs. 0.3%, p=0.07). There was a statistically significant difference in the number of appendectomies in the germfibrozil group (6/311 vs. 0/317, p=0.029).

PRECAUTIONS Initial therapy: Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting TRICOR therapy. Every stempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridenia (beta-blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Continued therapy: Periodic determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective dose of TRICOR. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 145 mg per day. Pancreatific: Pancreatifis has been reported in patients taking fenofibrate, genfibrozil, and clofibrate. This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct. Hypersensitivity Reactions: Acute hypersensitivity reactions including severe skin rashes requiring patient hospitalization and treatment with steroids have occurred very rarely during treatment with fenofibrate, including rare spontaneous reports of Stevens-Johnson syndrome, and toxic epidermal necrolysis. Urticaria was seen in 1.1 vs. 0%, and rash in 1.4 vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials. Hematoloeic Channese: Mild to moderate hemoelobin hematocrit, and white PRECAUTIONS

necrolysis. Urticaria was seen in 1.1 vs. 0%, and rash in 1.4 vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials. **Hematologic Changes:** Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibrate therapy. However, these levels stabilize during long-term administration. Extremely rare spontaneous reports of thrombocytopenia and agranulocytosis have been received during post-marketing surveillance outside of the U.S. Periodic blood counts are recommended during the first 12 months of TRUCOB administration nths of TRICOR adu

Subside of the CST relation to boost of units are recommended during the first re-months of TRICOR administration. Skeletal muscle: The use of fibrates alone, including TRICOR, may occasionally be associated with myopathy. Treatment with drugs of the fibrate class has been associated on rare occasions with rhabdomyolysis, usually in patient with impaired renal function. Myopathy should be considered in any patient with diffuse myalgias, muscle tendemess or weakness, and/or marked elevations of creatine phosphokinase levels. Patients should be advised to report promptly unexplained muscle pain, rendermess or weakness, particularly if accompanied by malaise of rever. CPK levels should be assessed in patients reporting these symptoms, and fenofibrate therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed. Drug Interactions Oral Anticoagulants: CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION

COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTLL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-COA reductase inhibitors: The combined use of TRICOR and HMG-COA reductase inhibitors: The combined use of TRICOR and HMG-coA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS).

Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile

patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption. **Cyclosporine:** Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fobrate drugs including TRICOR (fenofibrate tablets), there is a risk that an interaction will lead to deterioration. The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed.

Immunosuppressing and other lowest effective dose employed. **Carcinogenesis, Mutagenesis, Impairment of Fertility:** Two dietary carcinogenicity studies have been conducted in rats with fenofibrate. In the first 24-month study, rats were dosed with fenofibrate at 10, 45, and 200 mg/kg/day, approximately 0.3, 1, and 6 times the maximum recommended human dose (MRHD) of 145 mg/day, based on mg/meter² of surface area). At a dose of 200 mg/kg/day (at 6 times the MRHD), the incidence of liver carcinomas was significantly increased in both sexes. A statistically significant increase in pancreatic carcinomas was observed in males at 1 and 6 times the MRHD; an increase in pancreatic adenomas and benign testicular interstitial cell tumors was observed at 6 times the MRHD (0.3 males. In a second 24-month study in a different strain of rats, doses of 10 and 60 mg/kg/day (0.3 and 2 times the MRHD based on mg/meter² surface area) produced significant increases in the incidence of pancreatic acinar adenomas in both sexes and increases in testicular interstitial cell tumors in males at 2 times the MRHD (200 mg/kg/day). es the MRHD (200 mg/kg/day).

times the MRHD (200 mg/kg/day). A 117-week carcinogenicity study was conducted in rats comparing three drugs: fenofibrate 10 and 60 mg/kg/day (0.3 and 2 times the MRHD), clofibrate (400 mg/kg/day; 2 times the human dose), and Gemfibrozil (250 mg/kg/day; 2 times the human dose) (multiples based on mg/meter² surface area). Fenofibrate increased pancreatic acinar adenomas in both sexes. Clofibrate increased hepatocellular carcinoma and pancreatic acinar adenomas in males and hepatic neoplastic nodules in females. Gemfibrozil increased hepatic nodules in males and females, while all three drugs increased testicular interstitial cell tumors in males. n a 21 month study in mice fanofibrate 10.0 dS and 200 mg/kg/day

Increased nepatch neoplastic nodules in males and remales, while all three drugs increased testicular interstitial cell tumors in males. In a 21-month study in mice, fenofibrate 10, 45, and 200 mg/kg/day (approximately 0.2, 0.7, and 3 times the MRHD on the basis of mg/meter² surface area) significantly increased the liver carcinomas in both sexes at 3 times the MRHD. In a second 18-month study at the same doses, fenofibrate significantly increased the liver carcinomas in male mice and liver adneomas in female mice at 3 times the MRHD. Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to her at. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsites were compared before and after treatment in the same individual. Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal aberration and unscheduled DNA synthesis.

the following tests: Ames, mouse lymphoma, chromosomai aberration and unscheduled DNA synthesis. Pregnancy Category C: Safety in pregnant women has not been established. Fenofibrate has been shown to be embryocidal and teratogenic in rats when given in doses 7 to 10 times the maximum recommended human dose (MRHD) and embryocidal in rabbits when given at 9 times the MRHD (on the basis of mg/meter² surface area). There are no adequate and well-controlled studies in pregnant women. Fenofibrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Administration of approximately 9 times the MRHD of 145mg/day of fenofibrate to female rats before and throughout gestation caused 100% of dams to delay delivery and resulted in a 60% increase in post-implantation loss, a decrease in litter size, a decrease in birth weight, a 40% survival of pups at birth, a 4% survival of pups as neonates, and a 0% survival of pups to weaning, and an increase in spina bifda. Administration of approximately 10 times the MRHD to female rats on days 6-15 of gestation caused an increase in gross, visceral and skeletal findings in fetuses (domed head/hunched shoulders/rounded body/abnormal chest, kyphosis, stunted fetuses, clongated sternal ribs, malformed sternebrae, extra foramen in palatine, misshapen vertebrae, supernumerary ribs). Administration of approximately 7 times the MRHD to female rats from day 15 of gestation through weaning caused a delay in delivery, a 40% decrease in live births, a 75% decrease in neonatal survival, and decreases in pup weight, at birth as well as on days 4 and 21 post-partum. Administration of fenofibrate at 9 to 18 times the MRHD to female rabbits caused abortions in 10% to 25% of dams and death in 7% of fetuses at 18 times the MRHD. **Nursing mothers:** Fenofibrate should not be used in nursing mothers. Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue unursing or to discontinue the drug. **Pediatric Use:** Safety and efficacy in pediatric patients have not been established.

Geriatric Use: Fenofibric acid is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection.

ADVERSE REACTIONS

ADVERSE REACTIONS CLINICAL: Adverse events reported by 2% or more of patients treated with fenofibrate during the double-blind, placebo-controlled trials, regardless of causality, are listed in the table below. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing nuation of fenofibrate treatment in 1.6% of patients in double-blind trials BODY SYSTEM Fenofibrate* Placebo

Adverse Event	(N=439)	(N=365)
BODY AS A WHOLE		
Abdominal Pain	4.6%	4.4%
Back Pain	3.4%	2.5%
Headache	3.2%	2.7%
Asthenia	2.1%	3.0%
Flu Syndrome	2.1%	2.7%
DIGESTIVE		
Liver Function Tests Abnormal	7.5%**	1.4%
Diarrhea	2.3%	4.1%
Nausea	2.3%	1.9%
Constipation	2.1%	1.4%
METABOLIC AND NUTRITIONAL DIS	ORDERS	
SGPT Increased	3.0%	1.6%
Creatine Phosphokinase Increased	3.0%	1.4%
SGOT Increased	3.4% **	0.5%
RESPIRATORY		
Respiratory Disorder	6.2%	5.5%
Rhinitis	2.3%	1.1%

Dosage equivalent to 145 mg TRICOR * Significantly different from Placebo

Additional adverse events reported by three or more patients in placebo controlled trials or reported in other controlled or open trials, regardless of causality are listed below.

BODY AS A WHOLE: Chest pain, pain (unspecified), infection, malaise, allergic reaction, cyst, hernia, fever, photosensitivity reaction, and accidental injury. CARDIOVASCULAR SYSTEM: Angina pectoris, hypertension, vasodilatation

oronary artery disorder, electrocardiogram abnormal, ventricular xtrasystoles, myocardial infarct, peripheral vascular disorder, migraine aricose vein, cardiovascular disorder, hypotension, papitation, vascula lisorder, arrhythmia, phlebitis, tachycardia, extrasystoles, and atria

fibrillation. *DIGESTIVE SYSTEM:* Dyspepsia, flatulence, nausea, increased appeti gastroenteritis, cholelithiasis, rectal disorder, esophagitis, gastritis, colit tooth disorder, vomiting, anorexia, gastrointestinal disorder, duodenal ulc DICESTIVE STSTEM: Dyspepsia, fratulence, nausea, increased appente, gastroenteritis, cholelithaissi, rectal disorder, esophagitis, gastritis, colitis, tooth disorder, vomiting, anorexia, gastrointestinal disorder, duodenal ulcer, nausea and vomiting, peptic ulcer, rectal hemorrhage, liver fatty deposit, cholecystitis, eructation, gamma glutamyl transpeptidase, and diarrhea. ENDOCRINE SYSTEM: Diabetes mellitus. HEMIC AND LYMPHATIC SYSTEM: Anemia, leukopenia, ecchymosis, respirateditis, hemothedraetathe and diverkeentarenterity.

eosinophilia, lymphadenopathy, and thrombocytopenia. METABOLIC AND NUTRITIONAL DISORDERS: Creatinine increased weight gain, hypoglycemia, gout, weight loss, edema, hyperuricemia, and

peripheral edema. MUSCULOSKELETAL SYSTEM: Myositis, myalgia, arthralgia, arthritis, tenosynovitis, joint disorder, arthrosis, leg cramps, bursitis, and myasthenia. NERVOUS SYSTEM: Dizziness, insomnia, depression, vertigo, libido decreased, anxiety, paresthesia, dry mouth, hypertonia, nervousness, <u>revention</u> and compolence

RESPIRATORY SYSTEM: Pharyngitis, bronchitis, cough increased, dyspnea, RESPIRATORY SYSTEM: Pharynguts, bronchits, cough increased, dyspnea, asthma, allergic pulmonary alveolitis, pneumonia, laryngitis, and sinustiis. SKIN AND APPENDAGES: Rash, pruritus, eczema, herpes zoster, urticaria, acne, sweating, fungal dermatitis, skin disorder, alopecia, contact dermatitis, herpes simplex, maculopapular rash, nali disorder, and skin utcer. SPECIAL SENSES: Conjunctivitis, eye disorder, amblyopia, ear pain, otitis media, abnormal vision, cataract specified, and refraction disorder. UROGENITAL SYSTEM: Urinary frequency, prostatic disorder, dysuria, abnormal kidney function, urolithiasis, gynecomastia, unintended pregnancy, vaeinal moniliasis, and cystifis.

aginal m niliasis, and cystitis OVERDOSAGE

UVENUUSAUE There is no specific treatment for overdose with TRICOR. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Because fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.

Reference: 03-5344-R1 Revised: November, 2004 05B-030-H528-1 MASTER

ABBOTT LABORATORIES NORTH CHICAGO, IL 60064 U.S.A.

06C-030-P148-2 Printed in U.S.A

cluded a blood glucose test and testing for dementia and Alzheimer's disease.

The mean follow-up was 5 years per person. By that time, borderline diabetes had been identified in 47 subjects and 397 had been diagnosed with dementia (307 with Alzheimer's).

After controlling for vascular risk factors, borderline diabetes was associated with a 67% increased risk for developing a dementia and a 77% increased risk for developing Alzheimer's, Dr. Fratiglioni said. Additional analysis found that the risk was increased yet again in those with borderline diabetes who also had a systolic blood pressure of 180 mm Hg or higher.

Metformin Cuts BMI in **At-Risk Teens**

BOSTON — Metformin was associated with weight loss that persisted at 12 months in obese adolescents at risk for diabetes, Dr. Dorit Koren said at the annual meeting of the Endocrine Society.

On the basis of the results of this small retrospective study, metformin should be submitted to further testing as a tool in the prevention of diabetes in high-risk, obese teens, she said. In previous studies of similar patients, metformin has been associated with short-term weight loss, as well as improvements in glucose levels, lipid abnormalities, and hyperandrogenism.

To determine whether the weight losses persisted at 12 months, Dr. Koren and colleagues at St. Christopher's Hospital for Children, Philadelphia, reviewed the charts of 26 nondiabetic adolescents seen in that institution's endocrine clinic. Their mean age was 14 years, and their body mass indexes were above the 95th percentile.

Metformin, 1,000 mg/day, was given to 14 of the teens because they had abnormal cholesterol values (HDL less than 40 mg/dL, triglycerides greater than 110 mg/dL) or fasting insulin levels greater than 20 μ U/mL, or because of menstrual irregularities associated with polycystic ovary syndrome. At baseline and at 6 and 12 months, all of the patients underwent height and weight evaluations to calculate BMI and blood tests to measure cholesterol, blood sugar, and insulin levels.

The BMI scores of the treated group declined from 2.50 times above the average measures for age and sex to 2.35 times above average, Dr. Koren said in a poster presentation. BMI did not significantly change in the untreated group. For the treated versus the untreated groups, changes in BMI baseline score were significantly different at 6 months and still within the range of significance at 12 months. Cholesterol measures were initially better in the metformin group, but the differences between the two groups were no longer statistically significant at 12 months.

Metformin might be viewed as a complement to dietary and exercise changes in obese adolescents, she said. Its long-term safety and efficacy in nondiabetic adolescents has yet to be confirmed. Dr. Koren reported no conflicts of interest.